HOXA9 and leukemia: In our study, using lentiviral shRNA on HOXA9-MEIS1 blasts to knock down CD45, we observed that these resulting cells had lost their capacity to induce leukemia in secondary transplantation settings, even after inoculation of the cells into bone marrow, thus highlighting the pivotal role of CD45 in the maintenance of leukemia in vivo.